|Day's Range||0.153 - 0.159|
|52 Week Range||0.140 - 0.980|
|PE Ratio (TTM)||-0.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.07 million, Net Earnings of USD -30.71 million. Change in operating cash flow of 36.29% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)
Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.
Northwest's inability to resolve the problems that froze the DCVax-L clinical trial -- and management's refusal to offer a public explanation for why it happened -- triggered the company's collapse.